Jakubowitz Law
(212) 867-4490
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (HSACW)

Immunovant is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401’s prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you incurred a loss on HSACW stocks purchased between October 2, 2019 and February 1, 2021, this lawsuit is on your behalf. The lawsuit was filed in the the United States District Court for the Eastern District of New York, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until April 20, 2021 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Fill out the form below to be contacted by a representative of Jakubowitz Law.

Loss Submission Form

See If you Qualify for Monetary Reward

Jakubowitz Law does not share your information with others.
There is no cost or obligation for you to submit

This submission does not create an attorney-client relationship.
If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss
whether to establish an attorney-client relationship.